H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)

February 11, 2025 6:47 AM EST Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $18.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login